ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma - European Medical Journal

ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma

Hematology

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label, randomised phase 3 ENDEAVOR study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given